Adaptive CRT in patients with normal AV conduction and left bundle branch block

Does QRS duration matter?

Hiro Yamasaki, Daniel Lustgarten, Jeffrey Cerkvenik, David Birnie, Maurizio Gasparini, Kathy Lia Fun Lee, Yukio Sekiguchi, Niraj Varma, Bernd Lemke, Randall C. Starling, Kazutaka Aonuma

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background Adaptive cardiac resynchronization therapy (aCRT) is a dynamic optimization algorithm which paces only the left ventricle (LV) when atrio-ventricular (AV) conduction is normal, thus reducing right ventricular (RV) pacing. However, the impact of QRS duration on aCRT efficacy remains uncertain. We examined whether QRS duration impacts aCRT effectiveness in patients with left bundle branch block (LBBB) and preserved AV conduction. Methods Randomized patients in the Adaptive CRT trial, which enrolled NYHA III/IV patients, were used in this analysis. Patients were randomized to receive aCRT or echo-optimized bi-ventricular CRT (control arm). Endpoints for this analysis were clinical composite score (CCS) at 6 months post-implant and time to first heart failure (HF) hospitalization or death. Results Among the 199 patients with LBBB and normal AV intervals at baseline, 80 patients (40%) had a baseline moderately wide QRS of 120–150 ms. In this subgroup, a greater proportion of aCRT patients had an improved CCS (79% vs. 50%) at 6 months compared to the control group (p = 0.03). There was also a trend toward a lower risk of death or HF hospitalization (hazard ratio: 0.53; 95% CI: 0.24–1.15; p = 0.10) in the moderately wide QRS subgroup with aCRT compared to the control arm. In the wide QRS subgroup, the efficacy was comparable in both treatment arms. Conclusion Adaptive CRT was associated with improved patient outcomes over echo-optimized bi-ventricular CRT in patients with preserved AV conduction, LBBB, and moderately wide QRS. The adaptive cardiac resynchronization therapy trial (ClinicalTrials.gov Identifier: NCT00980057) was sponsored by Medtronic plc, Mounds View, MN.

Original languageEnglish
Pages (from-to)297-301
Number of pages5
JournalInternational Journal of Cardiology
Volume240
DOIs
Publication statusPublished - Aug 1 2017

Fingerprint

Bundle-Branch Block
Cardiac Resynchronization Therapy
Hospitalization
Heart Failure
Heart Ventricles
Control Groups

Keywords

  • Adaptive CRT
  • Clinical response
  • QRS duration

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Adaptive CRT in patients with normal AV conduction and left bundle branch block : Does QRS duration matter? / Yamasaki, Hiro; Lustgarten, Daniel; Cerkvenik, Jeffrey; Birnie, David; Gasparini, Maurizio; Lee, Kathy Lia Fun; Sekiguchi, Yukio; Varma, Niraj; Lemke, Bernd; Starling, Randall C.; Aonuma, Kazutaka.

In: International Journal of Cardiology, Vol. 240, 01.08.2017, p. 297-301.

Research output: Contribution to journalArticle

Yamasaki, H, Lustgarten, D, Cerkvenik, J, Birnie, D, Gasparini, M, Lee, KLF, Sekiguchi, Y, Varma, N, Lemke, B, Starling, RC & Aonuma, K 2017, 'Adaptive CRT in patients with normal AV conduction and left bundle branch block: Does QRS duration matter?', International Journal of Cardiology, vol. 240, pp. 297-301. https://doi.org/10.1016/j.ijcard.2017.04.036
Yamasaki, Hiro ; Lustgarten, Daniel ; Cerkvenik, Jeffrey ; Birnie, David ; Gasparini, Maurizio ; Lee, Kathy Lia Fun ; Sekiguchi, Yukio ; Varma, Niraj ; Lemke, Bernd ; Starling, Randall C. ; Aonuma, Kazutaka. / Adaptive CRT in patients with normal AV conduction and left bundle branch block : Does QRS duration matter?. In: International Journal of Cardiology. 2017 ; Vol. 240. pp. 297-301.
@article{23d484d8fa4441e986ab6b1f0e54bc7d,
title = "Adaptive CRT in patients with normal AV conduction and left bundle branch block: Does QRS duration matter?",
abstract = "Background Adaptive cardiac resynchronization therapy (aCRT) is a dynamic optimization algorithm which paces only the left ventricle (LV) when atrio-ventricular (AV) conduction is normal, thus reducing right ventricular (RV) pacing. However, the impact of QRS duration on aCRT efficacy remains uncertain. We examined whether QRS duration impacts aCRT effectiveness in patients with left bundle branch block (LBBB) and preserved AV conduction. Methods Randomized patients in the Adaptive CRT trial, which enrolled NYHA III/IV patients, were used in this analysis. Patients were randomized to receive aCRT or echo-optimized bi-ventricular CRT (control arm). Endpoints for this analysis were clinical composite score (CCS) at 6 months post-implant and time to first heart failure (HF) hospitalization or death. Results Among the 199 patients with LBBB and normal AV intervals at baseline, 80 patients (40{\%}) had a baseline moderately wide QRS of 120–150 ms. In this subgroup, a greater proportion of aCRT patients had an improved CCS (79{\%} vs. 50{\%}) at 6 months compared to the control group (p = 0.03). There was also a trend toward a lower risk of death or HF hospitalization (hazard ratio: 0.53; 95{\%} CI: 0.24–1.15; p = 0.10) in the moderately wide QRS subgroup with aCRT compared to the control arm. In the wide QRS subgroup, the efficacy was comparable in both treatment arms. Conclusion Adaptive CRT was associated with improved patient outcomes over echo-optimized bi-ventricular CRT in patients with preserved AV conduction, LBBB, and moderately wide QRS. The adaptive cardiac resynchronization therapy trial (ClinicalTrials.gov Identifier: NCT00980057) was sponsored by Medtronic plc, Mounds View, MN.",
keywords = "Adaptive CRT, Clinical response, QRS duration",
author = "Hiro Yamasaki and Daniel Lustgarten and Jeffrey Cerkvenik and David Birnie and Maurizio Gasparini and Lee, {Kathy Lia Fun} and Yukio Sekiguchi and Niraj Varma and Bernd Lemke and Starling, {Randall C.} and Kazutaka Aonuma",
year = "2017",
month = "8",
day = "1",
doi = "10.1016/j.ijcard.2017.04.036",
language = "English",
volume = "240",
pages = "297--301",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Adaptive CRT in patients with normal AV conduction and left bundle branch block

T2 - Does QRS duration matter?

AU - Yamasaki, Hiro

AU - Lustgarten, Daniel

AU - Cerkvenik, Jeffrey

AU - Birnie, David

AU - Gasparini, Maurizio

AU - Lee, Kathy Lia Fun

AU - Sekiguchi, Yukio

AU - Varma, Niraj

AU - Lemke, Bernd

AU - Starling, Randall C.

AU - Aonuma, Kazutaka

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Background Adaptive cardiac resynchronization therapy (aCRT) is a dynamic optimization algorithm which paces only the left ventricle (LV) when atrio-ventricular (AV) conduction is normal, thus reducing right ventricular (RV) pacing. However, the impact of QRS duration on aCRT efficacy remains uncertain. We examined whether QRS duration impacts aCRT effectiveness in patients with left bundle branch block (LBBB) and preserved AV conduction. Methods Randomized patients in the Adaptive CRT trial, which enrolled NYHA III/IV patients, were used in this analysis. Patients were randomized to receive aCRT or echo-optimized bi-ventricular CRT (control arm). Endpoints for this analysis were clinical composite score (CCS) at 6 months post-implant and time to first heart failure (HF) hospitalization or death. Results Among the 199 patients with LBBB and normal AV intervals at baseline, 80 patients (40%) had a baseline moderately wide QRS of 120–150 ms. In this subgroup, a greater proportion of aCRT patients had an improved CCS (79% vs. 50%) at 6 months compared to the control group (p = 0.03). There was also a trend toward a lower risk of death or HF hospitalization (hazard ratio: 0.53; 95% CI: 0.24–1.15; p = 0.10) in the moderately wide QRS subgroup with aCRT compared to the control arm. In the wide QRS subgroup, the efficacy was comparable in both treatment arms. Conclusion Adaptive CRT was associated with improved patient outcomes over echo-optimized bi-ventricular CRT in patients with preserved AV conduction, LBBB, and moderately wide QRS. The adaptive cardiac resynchronization therapy trial (ClinicalTrials.gov Identifier: NCT00980057) was sponsored by Medtronic plc, Mounds View, MN.

AB - Background Adaptive cardiac resynchronization therapy (aCRT) is a dynamic optimization algorithm which paces only the left ventricle (LV) when atrio-ventricular (AV) conduction is normal, thus reducing right ventricular (RV) pacing. However, the impact of QRS duration on aCRT efficacy remains uncertain. We examined whether QRS duration impacts aCRT effectiveness in patients with left bundle branch block (LBBB) and preserved AV conduction. Methods Randomized patients in the Adaptive CRT trial, which enrolled NYHA III/IV patients, were used in this analysis. Patients were randomized to receive aCRT or echo-optimized bi-ventricular CRT (control arm). Endpoints for this analysis were clinical composite score (CCS) at 6 months post-implant and time to first heart failure (HF) hospitalization or death. Results Among the 199 patients with LBBB and normal AV intervals at baseline, 80 patients (40%) had a baseline moderately wide QRS of 120–150 ms. In this subgroup, a greater proportion of aCRT patients had an improved CCS (79% vs. 50%) at 6 months compared to the control group (p = 0.03). There was also a trend toward a lower risk of death or HF hospitalization (hazard ratio: 0.53; 95% CI: 0.24–1.15; p = 0.10) in the moderately wide QRS subgroup with aCRT compared to the control arm. In the wide QRS subgroup, the efficacy was comparable in both treatment arms. Conclusion Adaptive CRT was associated with improved patient outcomes over echo-optimized bi-ventricular CRT in patients with preserved AV conduction, LBBB, and moderately wide QRS. The adaptive cardiac resynchronization therapy trial (ClinicalTrials.gov Identifier: NCT00980057) was sponsored by Medtronic plc, Mounds View, MN.

KW - Adaptive CRT

KW - Clinical response

KW - QRS duration

UR - http://www.scopus.com/inward/record.url?scp=85017475755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017475755&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2017.04.036

DO - 10.1016/j.ijcard.2017.04.036

M3 - Article

VL - 240

SP - 297

EP - 301

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

ER -